Victory Capital Management Inc. Purchases 186 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Victory Capital Management Inc. boosted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,294 shares of the medical research company’s stock after buying an additional 186 shares during the quarter. Victory Capital Management Inc. owned approximately 0.08% of Bio-Rad Laboratories worth $7,125,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Bio-Rad Laboratories by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 2,421,334 shares of the medical research company’s stock valued at $837,467,000 after acquiring an additional 31,445 shares during the last quarter. UniSuper Management Pty Ltd boosted its holdings in shares of Bio-Rad Laboratories by 585.4% during the 1st quarter. UniSuper Management Pty Ltd now owns 2,865 shares of the medical research company’s stock valued at $991,000 after buying an additional 2,447 shares in the last quarter. Natixis lifted its holdings in shares of Bio-Rad Laboratories by 3.4% during the first quarter. Natixis now owns 1,986 shares of the medical research company’s stock valued at $687,000 after purchasing an additional 65 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Bio-Rad Laboratories in the first quarter worth $51,000. Finally, Toronto Dominion Bank lifted its stake in shares of Bio-Rad Laboratories by 1.8% in the first quarter. Toronto Dominion Bank now owns 12,839 shares of the medical research company’s stock worth $4,441,000 after buying an additional 228 shares in the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Trading Up 0.7 %

Shares of Bio-Rad Laboratories stock opened at $325.99 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The stock has a market cap of $9.13 billion, a PE ratio of -11.93 and a beta of 0.93. The firm has a fifty day moving average price of $340.38 and a 200 day moving average price of $315.33. Bio-Rad Laboratories, Inc. has a 1 year low of $262.12 and a 1 year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company had revenue of $649.70 million during the quarter, compared to analyst estimates of $628.18 million. During the same period in the previous year, the business earned $2.33 EPS. Bio-Rad Laboratories’s quarterly revenue was up 2.8% on a year-over-year basis. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 9.93 earnings per share for the current year.

Insiders Place Their Bets

In related news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the transaction, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. The trade was a 28.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the transaction, the executive vice president now owns 147 shares of the company’s stock, valued at approximately $48,582.03. This trade represents a 80.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BIO has been the topic of a number of research reports. Citigroup raised their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company began coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target for the company. Royal Bank of Canada increased their price target on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Finally, StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $391.80.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.